54359-54-5

Basic information

• Product Name: Methanone, (2-amino-4-methyl-3-thienyl)(4-chlorophenyl)-
• Synonyms: (2-amino-4-methylthiophen-3-yl)(4-chlorophenyl)methanone;(2-amino-4-methyl-thiophen-3-yl)-(4-chloro-phenyl)-methanone
• CAS NO: 54359-54-5
• Molecular Formula: C12H10ClNOS
• Molecular Weight: 251.737
• Mol File: 54359-54-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 148 - 150 °C
• CAS DataBase Reference: Methanone, (2-amino-4-methyl-3-thienyl)(4-chlorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Methanone, (2-amino-4-methyl-3-thienyl)(4-chlorophenyl)-(54359-54-5)
• EPA Substance Registry System: Methanone, (2-amino-4-methyl-3-thienyl)(4-chlorophenyl)-(54359-54-5)

Safety Data

• Hazardous Substances Data: 54359-54-5(Hazardous Substances Data)

Upstream product

• 1126-46-1 Methyl 4-chlorobenzoate 
• 74-11-3 para-chlorobenzoic acid 
• 55704-78-4 2,5-dihydroxy-2,5-dimethyl-1,4-dithiane 
• 4640-66-8 p-chlorobenzoylacetonitrile 

Downstream Products

• 1027493-28-2 2-[3-(4-chloro-benzoyl)-4-methyl-thiophen-2-yl]-isoindole-1,3-dione 

Relevant articles and documents

6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE

The 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives or salts thereof of the present invention have BRD4 inhibitory activity, and thus, they are useful as medicaments, in particular, as prophylaxis and/or therapeutic agents for diseases associated with BRD4.

FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS

The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.

ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR

The present invention provides compounds of formula (I) wherein W, R1, R5 and R6 have a meaning as defined herein in the specification. The compounds of formula (I) are allosteric enhancers of the A1 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A1 adenosine receptor. Accordingly, the compounds of formula (I) may be employed for treatment of pain, in particular, chronic pain such as neuropathic pain, and inflammatory pain, cardiac disease or disorder such as cardiac disarrhythmias, e.g., peroxysmal supraventricular tachycardia, angina, myocardial infarction and stroke, neurological disease or injury, sleep disorders, epilepsy and depression.